Ivermectin reduces the risk of death from COVID-19 – a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance

Lawrie et al., Preprint, Jan 2021

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.0000000001 from 106 studies, recognized in 24 countries.

No treatment is 100% effective.
Protocols combine treatments.

Meta analysis confirming the effectiveness of ivermectin for COVID-19, showing ivermectin treatment mortality relative risk RR 0.17 [0.18-0.35] and prophylaxis cases RR 0.12 [0.08-0.18].
7 meta-analyses show significant improvements with ivermectin for mortality1-6, hospitalization7, recovery3, and cases3.
Currently there are 106 ivermectin for COVID-19 studies, showing 47% lower mortality [34‑58%], 35% lower ventilation [17‑50%], 40% lower ICU admission [12‑58%], 34% lower hospitalization [21‑44%], and 79% fewer cases [69‑86%].
OutcomeImprovementEffect · pTreatmentControl
risk of death 83.0% lower · RR 0.17 · p < 0.001*** 83.0% lowerRR 0.17p < 0.001*** 8 of 585 (1.4%) 44 of 522 (8.4%) treatment 8 of 585 (1.4%), control 44 of 522 (8.4%)NNT 14

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. *** p < 0.001

Lawrie et al., 3 Jan 2021, preprint, 1 author.